news and announcements

News and Announcements


In an effort to provide well-characterized monoclonal antibodies to the scientific community, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein...

May 1, 2018   |   Read More

An estimated 252,710 new cases of female breast cancer, accounting for 15% of all new cancer cases, occurred in 2017. To better understand proteogenomic abnormalities in breast cancer, the National Cancer Institute (NCI) Clinical...

April 23, 2018   |   Read More

Precision medicine is an approach that allows doctors to understand how a patient's genetic profile may cause cancer to grow and spread, leading to...

April 20, 2018   |   Read More

Mutations in the RAS genes — KRAS, HRAS, and NRAS — have been identified in approximately 30% of all human cancers. While RAS gene family members encode proteins that are pivotal for cytoplasmic cell signaling, RAS oncogenes...

April 12, 2018   |   Read More

Ionizing radiation (IR) is a commonly employed cancer treatment that kills cancer cells by damaging their DNA. While the DNA damage response (DDR) pathway may be key to determining tumor responses, radiochemical...

April 2, 2018   |   Read More

The Office of Cancer Clinical Proteomics Research at the National Cancer Institute, part of the United States National Institutes of Health, is spearheading the preparationand training of the proteogenomic research workforce on an international scale.

March 21, 2018   |   Read More

Breast cancer is the second most common cancer in women living in the United States, with triple-negative breast cancer (TNBC) accounting for approximately 15% of diagnoses. While chemotherapy is the standard-of-care in TNBC, resistance is common...

March 12, 2018   |   Read More

A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying diagnostics and therapies that will improve patients’ lives. Because a comprehensive molecular view of cancer is important for ultimately guiding treatment, the National Cancer Institute (NCI...

March 5, 2018   |   Read More

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce that teams led by Jaewoo Kang (Korea University), and Yuanfang Guan with Hongyang Li (University of Michigan) as the best performers of the NCI-CPTAC DREAM Proteogenomics Computational...

February 6, 2018   |   Read More

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the release of the cancer proteome confirmatory colon study data. The goal of the study is to analyze the proteomes of approximately 100 confirmatory colon tumor patients, which includes tumor and...

December 18, 2017   |   Read More

Pages